Background
49% of clinically diagnosed allergic rhinitis (AR) patients are
sensitized to house dust mite (HDM). If allergen avoidance and
symptomatic medication fail, allergen immunotherapy may be indicated. We
investigated safety and tolerability of HDM-sublingual immunotherapy HDM
SLIT-tablets in adults in daily clinical practice in the Netherlands.